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Summary We previously reported the production of a panel of murine monoclonal antibodies which
recognize glycoproteins abnormally expressed in human breast tumours. Using two of these antibodies, a
double antibody radioimmunoassay was designed to quantify levels of these breast tumour marker
glycoproteins in serum. Marker levels greater than 28 units were considered abnormal. Using this criterion,
63% and 75% of patients with breast cancer stages I and II, respectively, and 88% of those with metastatic
disease were found to have elevated marker levels. Thirteen percent of patients with non-malignant breast
disease also had elevated marker levels. Elevated marker levels were also detected in patients with non breast
neoplasms. One hundred and eleven women with metastatic disease were followed. Eighty-two percent of
those with progressive disease and 73% of those where disease regressed had 20% changes in marker levels.
These changes in marker levels preceded by up to 6 months changes in disease state. From these results we
conclude that this assay may be useful for monitoring the course of disease in breast cancer patients.
Ceriani et al. (I1982) were the first to detect significant
elevations of epithelial membrane antigens (EMA) in the
sera of patients with advanced breast cancer using polyclonal
antibodies produced against defatted human milk fat globule
membrane. Burchell et al. (1984) later developed a
quantitative double antibody serum assay by using
monoclonal antibodies to human milk fat globule membrane
antigens. Other investigations have also reported the
presence of related breast tumour markers in the sera of
breast cancer patients (Thompson et al., 1983; Papsidero et
al., 1984; Haynes et al., 1985). Hilkens et al. (1986) followed
a series of advanced breast cancer patients over a period of
one to six months to correlate circulating antigen levels
with the clinical course of the disease; the study examined a
small sample size.
We previously reported the production and
characterization of a panel of monoclonal antibodies reactive
with components of the EMA complex expressed at high
levels in human breast tumours (Major et al., 1987a; Dion et
al., 1987). These antibodies react with two high molecular
weight glycoproteins expressed in the majority of both
primary and metastatic lesions. The panel of antibodies
defines six epitopes present on molecules with apparent
molecular weights of 300,000 and 280,000 daltons.
Immunoblots of sera reveal that identical molecules are
present in the circulation of patients with disseminated
breast cancer (Major et al., 1987a). We have used two of
these antibodies to develop a double determinant
radioimmunoassay for quantifying circulating marker levels.
We report our results on the correlation of serum marker
levels and clinical course in patients with metastatic breast
cancer. In addition, serum marker levels were determined in
patients with primary breast cancer and benign disease.
Materials and methods
Serum samples
Blood samples were allowed to clot and then were
centrifuged for 15 min at 800g. The serum fraction was
collected and 0.02% sodium azide was added to prevent
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bacterial growth. The serum was immediately frozen at
-20 C. Normal sera were collected from apparently healthy
women. Sera from patients with benign breast disease and
primary breast cancer who had no clinical evidence of
metastases were obtained prior to surgery. The clinical
staging of patients with primary breast cancer was according
to the system of the UICC (International Union Against
Cancer). Serial blood samples for tumour marker, SMA-16
and CEA (CEA-EIA Roche, Nutley, New Jersey, USA) were
collected at each clinic visit from patients with metastatic
cancer. This group included 27 newly diagnosed cases
initiating treatment; the other 84 patients had been treated
previously and were being followed without therapy or were
starting new courses of treatment. Samples were drawn at
least two weeks after chemotherapy. Patients with an
elevated bilirubin or a life expectancy of less than 6 months
were not entered into the trial. The upper limit of normal for
CEA was set at 5ngml-1. Sera from patients with widely
disseminated malignancies other than breast cancer were also
collected. When laboratory tests (X-rays, nuclear imaging,
computed tomography) were positive, they were repeated at
2-4 months during treatment and thereafter when clinically
appropriate. Stable disease, progression or regression were
assessed according to the criteria previously used by
Swenerton et al. (1979) for evaluating treatment response in
patients with metastatic breast carcinoma. In the stable
disease group all but 3 patients had a minimum follow-up of
6 months between evaluations without evidence of disease
change. The exceptions were two patients who had a 3
month follow-up and one, a 5 month follow-up. The latter 3
patients were included when correlating marker value with
disease. When estimating lead time, the time of observing
progression or regression was compared to the time of rise
or fall of breast tumour marker levels.
Serum samples were received with a patient information
form indicating to which of the above groups the patient
belonged. Samples were assigned numbers based on the
order of accrual. Consecutive samples were assayed in
batches. At the end of the study the clinical charts were used
to verify the diagnosis and staging of all patients. In the case
of patients with metastatic disease the information in patient
information forms detailing the clinical course of their
disease was verified in their hospital and clinical records and
transferred to a flow sheet. At the end of the study the
serum marker levels were entered on the flow sheet for
compilation and statistical analysis.
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Antibody production and radiolabelling
The production and characterization of monoclonal
antibodies MA6 and MA9 have been previously described
(Major et al., 1987a; Dion et al., 1987). Ascites was
produced in either BALB/c (Charles River, St-Constant,
Quebec) or CAFI mice (Jackson Labs, Maine) for MA6 and
MA9, respectively. Mice were injected i.p. with 0.5ml 2, 6,
10, 14-tetramethylpentadecane (Sigma Chemical, St. Louis,
Missouri) 13 days and 3 days prior to injection of 5 x 106
hybridoma cells. Ascites was collected 3 to 4 weeks later.
Ascites fluid was first precipitated with 50% ammonium
sulphate and then purified by sieve chromatography on
AcA-34 gel (LKB, Bromma, Sweden, from Fisher Scientific,
Canada). Antibody purity was verified by SDS
polyacrylamide gel-electrophoresis. The purified antibody
was labeled with NaI125 (Amersham Corporation, Oakville,
Ontario) using the IODO-GEN method (Pierce Chemical
Company, Rockford, Illinois). The usual yield of the
labelling reaction was 106 cpmpg- 1 antibody.
Double antibody radioimmunoassay and standardization
The sera of breast cancer patients contain antigen of the
same molecular weight as that found in the membrane
fractions of breast tumours (Major et al., 1987a); a tumour
membrane enriched preparation, MB5 (Major et al., 1987a),
was used as source of antigen. The tumour membrane
enriched preparation, MB5, was sonicated, aliquoted and
stored in liquid nitrogen; this MB5 standard gives a
homogeneous solution when dissolved in 0.9% NaCl. Assay
standards were prepared as follows:
1. A fresh thawed 10yl aliquot of MB5 standard was
combined with 490,ul of serum from a normal female
whom we designated as LS.
2. Then, volumes of 0, 10, 20,..., 90,ul of the above
antigen preparation were added to LS normal serum to
a final total volume of I00,ul.
3. Finally, 1:4 dilutions of the latter preparation were
made using dilution buffer (wash buffer as defined
below containing 0.5% bovine albumin).
These dilutions were defined as containing 0, 10, 20,..., 90
units (U) of antigen per 504u1. Antigen diluted in this manner
gave a linear standard curve (Figure 1). Serum from the
normal female LS was used in the dilution of antigen
standards because her serum gave the lowest signal (LS) in
our control panel of normal sera.
Patient sera to be assayed were initially diluted 1:4 in
buffer; all further dilutions were made in a solution of 3
parts dilution buffer and 1 part LS serum. All incubations
were done at 37°C in a humidified chamber.
Polyvinylchloride microtitration plates with round bottom
wells (Fisher Scientific, Montreal, Canada) were coated with
4pg per well of antibody MA9 in 50p1 PBS and allowed to
adsorb for 16h. Unbound antibody was removed and 300p1
blocking buffer (0.5% BSA, 0.02% sodium azide in PBS, pH
7.4) was added to the antibody coated wells for 30min. The
plates were then washed twice with wash buffer (0.05 M
phosphate, 0.5 M NaCl, 0.1% Tween 20 pH 8.0). Serum
samples diluted as described above were added to blocked
wells and incubated for 2h. Following two rinses with wash
buffer, 0.1 pug labelled antibody MA6 was added and
incubated for 2h. After 4 rinses with wash buffer, the wells
were cut out and counted.
Statistical analysis
All statistical analyses were performed on an IBM PC using
the SPSS PC+ statistical analysis program (SPSS Inc.,
Chicago, USA). The logarithm of the marker values was
used for analysis. We used Pearson's linear correlation
coefficient to identify any relationship between age and
marker values in our normal control population. We took
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Figure 1 Standard curve obtained from the mean of 6
independent assays performed on consecutive days. The straight
line was fitted through the origin by the method of least squares.
The assay is linear up to 90 antigen units. Bars indicate the
standard deviations.
into account the possible interaction between groups and age
when seeking to identify any relation between age and
marker values in our patient population; for this purpose we
used multiple hierarchical regression analysis (Draper &
Smith, 1981). We did one way analysis of variance followed
by Student-Newman-Keuls multiple comparison of means
(Sokal & Rohlf, 1981) to compare marker values in our
control and patient groups. Kendall's tau B test was used as
a measure of association between ordinal variables.
Results
Assay characteristics
Linearity The standard curve generated with MB5 antigen
is linear up to 90U. Standard curves were generated with
quintuplicate values at each point on 6 different days; Figure
1 illustrates these results. The standard curves are consistent
from day to day.
Stoichiometry To enable us to assay samples with marker
levels outside the linear range of the standard curve, the
stoichiometry of the assay was examined. Serum samples
were diluted to give signals below 90U. As an example,
800U of MB5 antigen was added to a 50pl serum sample.
This antigen-spiked sample was diluted 1: 16 to yield a
sample containing 50U. The assay value of this latter sample
(2723cpm+ 150) is comparable to that of the 50U standard
(2556cpm+91).
Reproducibility We studied within-day and between-day
assay variations by assaying several samples in quintuplicate
on 3 to 6 different days. Representative results for 4 serum
samples are shown in Table I. The average of the coefficients
of variation (Kennedy, 1984) is 5.6% for between-day
variations and 5.1% for within-day variations. Within-day
standard deviations of quintuplicate points never exceed
10% of the mean.
Specifcity The assay of undiluted serum yields a high
background signal. This signal interference from serum364 R.L. SCHECTER et al.
Table I Within-day assay variation in serum samples was determined by measuring
marker in quintuplicate. Between-day assay variation was measured by quantifying
levels of marker in assays performed on different days. The values shown are the
average of quintuplicates+s.d.
Day Serum sample 1 Serum sample 2 Serum sample 3 Serum sample 4
2
3
4
5
6
Mean
41+4.0U
41+3.0U
39+3.8 U
38+3.0 U
40+4.0 U
39+2.2 U
39.7+2.40U
49+1.2U 69+1.6U 86+4.OU
50+2.1 U 69+2.0U 87+5.0U
49+2.3U 70+1.3U 84+5.5U
- - 85+4.OU
- - 84+6.0U
- - 84+3.0U
49.3+0.57 U 69.3 +0.57U 85+2.5U
factors can be diluted out as shown by the following
experiment: a serum sample from a breast cancer patient
with disseminated disease was diluted 1:128 in buffer. Ten to
60 1l of this preparation was then assayed as above. As
shown in Figure 2, the curve is linear and passes through the
origin.
Marker levels in normalfemales and patients with benign
breast disease
The mean marker value for all healthy women (Table II) was
13 U. The upper limit of normal was set at 28 U and includes
95% of normal women. Nineteen of our healthy females
were followed over 24 to 36 months and had 4 to 6 serum
samples drawn; marker value fluctuations were < 10%.
Regression analysis showed no statistically significant
association between age and marker levels (P=0.23).
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The sera of 4 pregnant and 2 lactating females were also
assayed for antigen; no elevations in antigen were detected.
Marker level fluctuations observed in 5 healthy
premenopausal women during the menstrual cycle were
within the limits of assay variation. Four of 29 patients with
benign breast disease (as determined by clinical exam and
mammography) showed elevations in marker (Figure 3).
Marker levels in patients with malignancies other than
breast cancer
We tested the sera of 37 patients with various non-breast
malignancies for circulating marker. All patients selected
were in advanced stages of their disease with multiple
visceral and/or bone metastases. As shown in Table III, 49%
of these patients were positive for marker. These patients
had malignancies originating in secretory epithelia. None of
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Figure 2 Assay specificity. A positive serum sample was diluted
1:128 in buffer. Ten to 601p diluted serum was then assayed as
described in Materials and methods. Each point is the mean of
quintuplicates. The curve is linear and passes through the origin.
Table II Mean age (X), standard deviation (s.d.) and number (n) of
subjects in groups
X s.d. n
Normal females: non smokers 44.14 8.05 42
Normal females: smokers 50.16 9.32 19
Benign breast disease: 46.79 11.17 29
Stage I breast cancer: 57.15 14.45 27
Stage II breast cancer: 58.29 13.46 24
Stage III breast cancer: 63.14 12.48 7
Metastatic breast cancer: 56.11 11.50 111
Normal Benign IIIl Metastatic
females breast
disease Breast cancer stage
Figure 3 Marker levels in normal women, women with non-
neoplastic breast disease and women with breast cancer stages I,
II, III and with metastatic disease. Values shown are the mean of
triplicate points. The broken line at 28 units marks the upper
limit of normal.
Table III Levels of marker measured in patients with various non-
breast malignancies ofepithelial origin. Marker values shown are the
mean+s.d. Forty-nine percent of these patients had elevated marker
values
Number ofpatients
Tumour type positive/total Marker values (U)
Colon 8/9 48+ 12
Lung 3/6 29+ 15
Prostate 2/3 30+ 10
Melanoma 0/3 25 + 9
Ovary 2/3 45 + 13
Stomach 1/4 46+34
Pancreas 2/4 48 +22
Lymphoma 0/5 21+11
*1-
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the patients with either melanoma or lymphoma showed
elevated levels. Immunohistochemically, our antibodies react
with secretory epithelia other than breast to varying degrees,
though staining is always less intense than that which is
observed in normal breast tissue (Major et al., 1987a).
Evaluation of breast tumour marker in patients with breast
cancer
Patients with breast cancer comprised four groups: those
with primary tumours stages I, II, III and patients with
metastatic disease. Fifty eight patients with pathologically
staged primary breast carcinoma were evaluated for marker
levels; 38 patients (66%) had elevated levels of antigen
(Figure 3). In those patients with Stage I disease, 63% had
abnormal antigen levels, whereas 75% of women with Stage
II disease were marker positive. Three of the 7 stage III
patients had elevated levels.
We measured breast tumour marker and CEA serum
levels in 39 consecutive patients with metastatic breast
cancer. These results are summarized in Table IV. Thirty
eight of these patients (97%) showed elevated breast tumour
marker levels, but only 46% of the patients had elevated
CEA values. CEA monitoring was omitted in subsequent
patients.
In 111 patients with metastatic disease, 88% had elevated
marker levels. These data are summarized in Figure 3.
Patients with metastatic disease had a mean level of 188U,
well above the mean of any other stage. Circulating marker
levels in patients with bone lesions are higher than in
patients with visceral metastases. Marker levels are highest in
patients with both bone and visceral disease. There is,
however, significant overlap in marker levels between these
groups. The results are summarized in Table V.
The mean age of subjects in our groups was different
(Table II) thus we needed to rule out any significant effect of
age on marker levels. We first established that there was no
significant relation between age of patients and groups
(P=0.24). Regression analysis which took into account the
groups allowed us to establish that there was no significant
relation between age and marker levels (age effect: P=0.27;
group effect: P<0.0001). The groups were then compared
for mean marker levels using one way analysis of variance.
The Student-Neuman-Keuls multiple comparison procedure
was applied following one way analysis of variance. This
revealed significant differences between the groups
(P<0.0001). The multiple comparison procedure results are
summarized in Table VI. Smoking or non-smoking healthy
volunteers and those with benign breast disease did not
differ amongst themselves but were different from patients
Table IV Sites of disease in patients with elevated CEA
Site(s) of Number of CEA BTM
metastasis patients positive positive
Bone 11 5 11
Bone and lung 12 5 12
Bone and liver 7 5 7
Lung 3 1 3
Lung and liver 0 1
Lung, liver and bone 1 0 1
Local recurrence 3 1 3
Pulmonary lymphangitis 1 1 0
BTM: Breast tumour marker.
Table V Mean marker levels in patients with metastatic breast
cancer and the site of metastases at initial diagnosis. Marker values
are the mean+s.d.
Sites of metastases % patients Mean antigen value
Skin and nodes 22.9 69+5.7U
Bones 36.6 214+225 U
Viscera 20.7 129 + 145 U
Viscera and bones 19.8 342+225 U
Table VI Student-Neuman-Keuls multiple comparison procedure
X Groups HFNS HFS BBD PBI PBII MBC
2.2767 HFNS
2.3686 HFS
2.7768 BBD
3.4438 PBI $** *** ***
3.5803 PBII *** *** ***
4.7291 MBC * *** *** *** ***
X: Mean logarithm of the marker value; *: Indicates groups that
differ from each other; HFNS: Healthy females, non smokers; HFS:
Healthy females, smokers; BBD: Benign breast disease; PBI: Primary
breast cancer, stage I; PBII: Primary breast cancer, stage II; MBC:
Metastatic breast cancer.
with breast cancer. Amongst those patients with breast
cancer there was no difference between those with stage I or
II primary disease; both groups were, however, different
from patients with metastatic disease.
Variations in serum marker levels during the course of
disease in patients with metastatic breast cancer
We followed 111 patients with metastatic breast cancer.
Patients were divided into three groups: those with disease
progression, those with disease regression, and those with
stable disease.
We examined the association between changes in marker
values and changes in clinical state in patients with
metastatic breast cancer using the Kendall tau B test. For
this purpose we chose to compare two values of marker
level: the value at initial evaluation and the value at the time
of clinical determination of change in disease state. (In the
case of patients with stable disease the initial serum marker
value and the value at the time of the last clinical evaluation
were compared. At the close of the trial, two patients with
stable disease were noted who had their last serum sample
drawn more than 6 weeks prior to completing their clinical
reevaluation. These two patients were not reported in Table
VII leaving a total of 109 patients for this analysis). This
showed an optimal association when a 20% increase or
decrease in marker values was the criterion selected
(tau=0.78). These results are summarized in Table VII.
Amongst the 62 patients with disease progression, 51 (82%)
had increases of >20% in serum marker levels; none had
decreases of 20% or more. Thirty patients experienced a
regression of their disease; in 22 (73%) there was a larger
than 20% decrease in marker levels; no patients showed
increases of 20% or more. Four patients with stable disease
had a 20% increase in marker level and 2 patients showed a
20% decrease in marker; the other 11 had variations of less
than 20%. Overall these data indicate that changes in
marker level of 20% are quite specific.
The 6 false positives (the 4 patients with stable disease
who show a 20% increase in marker level and the 2 patients
with stable disease who show a 20% decrease in marker
level) markedly affect the sensitivity of the assay. Five of
these false positives had their change in marker value early
Table VII Variation in marker levels at time of last documentation
of stable disease or of clinical change. Row percentages indicate the
% of patients in the category indicated at top of each column
Increase of Less than Decrease of
20% or more 20% change 20% or more
Patients with 51 pt 11 pt 0pt
progressive 82% 18% 0%
disease
Patients with 4pt 1Ipt 2pt
stable disease 23% 65% 12%
Patients with 0pt 8pt 22pt
regression of 0% 27% 73%
disease366 R.L. SCHECTER et al.
on during their follow-up while all their subsequent marker
values showed variations of <20%.
The mean initial serum marker levels in the patients who
later experienced progression (201 U+ 193.01s.d.) regression
(279U+256s.d.) or who were stable (57U+48s.d.) appear
quite different. We classified subjects based on the proximity
of their initial marker values to the mean marker value of
subjects in the three groups. With these criteria only 10, 14
and 16% of patients with progression, regression or stable
disease repectively would have been classified correctly. This
indicates that initial marker values cannot be used for
predicting the clinical course of disease.
We next examined the predictive value of serial assay
measurement. These data are summarized in Table VIII. For
this purpose we used the criteria of a 20% change in marker
value from initial measurement to any one subsequent
measurement taken prior to the documented change in
disease state or establishment of stable disease. Patients
where no serum sample was obtained between entry and
time of disease documentation could not be included in this
analysis. Twenty five of the 109 patients from Table VII fell
into this category.
The two patients with stable disease not included in the
Table VII analysis, were, however, eligible for the analysis
reported in Table VIII. Eighty percent of patients whose
marker level increased by 20% subsequently showed clinical
progression of disease. Seventy-nine percent of patients
whose marker levels decreased by 20% subsequently showed
regression of their disease. One patient with progression
experienced a larger than 20% decrease in marker value on
one measurement during her follow-up and three patients
with regression had one increased value during the early part
of their follow-up.
Of the 33 patients with progression where 20% or greater
marker variations preceded clinical change (Table VIII), 23
patients (70%) displayed those changes more than 4 weeks
prior to progression; in 15 of those 23, marker changes
precede progression by more than 8 weeks. Of the 15
patients with regression where significant marker changes
preceded clinical change (Table VIII), 6 patients (40%)
displayed those decreases more than 4 weeks prior to
regression; in 5 of those 6, marker decreases gave lead times
of more than 8 weeks.
Discussion
Serum assays for quantifying tumour markers have been
used for monitoring the clinical course of ovarian and
gastrointestinal carcinoma (Bast et al., 1983; Del Villano et
al., 1983; Klug et al., 1984; Sekine et al., 1985). In breast
cancer, the marker that has been most extensively evaluated
is CEA. This marker, however, lacks sufficient sensitivity,
and variations in serum levels appear to correlate poorly
with the course of disease (Chu et al., 1973; Borthwick et al.,
1976; Haagensen et al., 1978; De Jong-Bakker et al., 1981).
Elevated levels of epithelial membrane antigen (EMA) were
Table VIII Variations in marker levels prior to last documentation
of stable disease or to clinical change. Row percentages indicate the
% of patients in the category shown at the left who had the
variation in marker indicated at the top of each column
Increase of Less than Decrease of
20% or more 20% change 20% or more
Patients with 33pt 7pt 1 Pt
progressive 81% 17% 2%
disease
Patients with 5pt 11 pt 3 pt
stable disease 26% 58% 16%
Patients with 3 pt 8 pt 15 pt
regression 11% 31% 58%
of disease
first detected in serum of patients with breast cancer using
polyclonal antibodies (Ceriani et al., 1982). More recently
monoclonal antibodies reactive with specific components of
the EMA complex have been used to detect these antigens in
the sera of patients with breast cancer (Thompson et al.,
1983; Burchell et al., 1984; Papsidero et al., 1984; Haynes et
al., 1985; Hilkens et al., 1986; Major et al., 1987a).
We designed a double antibody radioimmunoassay using
two monoclonal antibodies which both react with two
specific components of the EMA complex. This combination
of antibodies was selected for optimal specificity and
sensitivity and the assay was designed to quantify marker
levels.
The assay reported here is reproducible, linear from 0 to
90 U and stoichiometric beyond the linear range of the
standard curve. Decreasing the serum protein content of
samples by diluting in protein-free buffers leads to non-linear
relations between marker level and assay signal; we
determined that 1:4 dilutions of serum were optimal for
reducing background and maintaining assay sensitivity (data
not shown). Initially, all samples were diluted 1:4 in buffer
and further dilutions were done in 1:4 dilutions of a
reference serum (LS) to maintain the stoichiometry of the
assay. This represents a technical improvement over other
assays that have used end point dilution (Haynes et al.,
1985) or log-linear standard curves (Hilkens et al., 1986) for
quantifying marker levels. Our assay design simplifies
quantitative comparison of marker levels in samples
obtained serially and allows the comparison of levels
between patient groups.
Pregnant and lactating females, in whom one might expect
to find higher than normal levels of antigen due to ductal
proliferation and milk fat globule secretion, do not show any
increased marker levels. Patients with benign breast disease
had elevations of marker levels in 13% of cases; these values
overlapped with those seen in patients with breast
malignancies. Elevated marker levels are observed in 63% of
Stage I and in 75% of Stage II patients with breast cancer.
This assay is not sufficiently sensitive or specific for
screening asymptomatic individuals.
The antigen recognized by our antibodies is detectable by
histochemistry in low levels in secretory epithelia other than
breast (Major et al., 1987a). We measured marker levels in
patients with malignancies originating in these tissues and
found only small elevations in cases of widely metastatic
disease. Use of the marker would appear to be limited to
patients with metastatic breast cancer.
There are several possible explanations for failing to detect
elevated levels of marker in patients with primary (or
metastatic) disease. The antibodies selected react with more
than 90% of primary tumours. However, our
immunoelectron microscopy studies (Major et al., 1987b)
show that in vivo primarily breast tumours may contain large
amounts of antigen in the cytoplasmic compartment and no
detectable antigen at the cell surface. Such tumours may not
shed antigen into the circulation. In addition, other
investigators have documented the presence of EMA
components in circulating immune complexes (Salinas et al.,
1987); antigen bound in such complexes might not be
detectable.
The initial evaluation of our assay shows a good
correlation between changes in marker level and changes in
the clinical status of patients with metastatic disease (Table
VII). Changes smaller than 20% are predictive of stable
disease in less than half the cases. More relevant to clinical
practice is that, in about half of the cases studied, significant
changes in marker occurred before clinical or laboratory
evaluation revealed changes in disease state (Table VIII).
This may reflect, in part, the ease of performing at each
clinic visit a test requiring only a serum sample. Radiographs
and nuclear medicine tests although repeated according to
standard medical practice guidelines were not done as
frequently. It is beyond the scope of this pilot study toBREAST TUMOUR MARKER RADIOIMMUNOASSAY 367
compare the sensitivity of standard tests with the serum
marker assay. Marker expression is heterogeneous in
tumours (Major et al., 1987a). A patient with a tumour
containing predominantly non marker secreting cells will
show a slower rise in marker level than a patient with a
tumour containing mostly marker positive cells. This may
explain the few cases where long lag-times for rises in
marker levels were observed after clinical documentation of a
change in disease state. Nevertheless our pilot study would
appear to warrant evaluating usefulness of this assay in
clinical practice for monitoring patients with metastatic
disease.
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